Biotech Bay is rich in opportunities in the hottest spaces of the industry
The Northern California Bay Area, which includes San Francisco, San Mateo, Santa Clara, Napa and Marin County, is home to some of the most established biopharmaceutical companies. The atmosphere is cold, the atmosphere relaxed – unless you work for one of those scientific innovators where it takes drive and determination to get the job done.
the Biotechnology bay The region is home to 3,418 life science companies and 96,574 employees who earn an average of $ 151,076. The goals and technologies range from cell and gene therapy to precision medicine and polymer chemistry, targeting rare diseases as well as more prevalent killers. And it turns out that these seven companies have a plethora of job openings right now.
Gilead Sciences Inc.
Nestled in Foster City, a small hamlet in San Mateo County, Gilead Sciences is well known for its achievements in viral diseases, most notably the human immunodeficiency virus (HIV).
With a mission to develop new therapies for life-threatening diseases with unmet medical needs, Gilead has an impressive list of drugs approved by the FDA. These include Veklury®, better known as COVID-19 therapy, remdesivir, Biktarvy®, a one-pill anti-HIV regimen, and Yescarta®, a chimeric antigen receptor (CAR-T) T cell drug acquired from Kite Pharma in 2017.
In 2020, Gilead employed approximatelyYes 13,600 people. This is an increase of around 2,000 (15.25%) from 2019, and the business is growing again.
For those passionate about global access to cancer drugs, Gilead is recruiting a Director, Value and Access Strategy – Oncology. The successful candidate will have at least 12 years of biopharmaceutical experience in market access related activities – bonus points if this is on a regional or national basis. For those more statically inclined, Gilead seeks a Senior Manager, Biostatistics – Oncology.
With more than 300 positions available, there are plenty of opportunities to join this Biotech Bay leader.
BioMarin Pharmaceutical Inc.
Founded in 1997, BioMarin, based in San Rafael, specializes in super rare diseases. BioMarin targets treatments for diseases such as inherited metabolic disorders, phenylketonuria (PKU) and the rapidly progressive pediatric brain disorder, neuronal ceroid lipofuscinosis type 2 (CLN2). The company is also very active in the field of hemophilia.
With six commercially approved drugs and a market capitalization of $ 15.4 billion, BioMarin was city by Zacks Equity Research as one of the four potential biotech buyout targets for 2021. Whether so, only time will tell, but BioMarin is still growing, with nearly 200 open positions, including:
Associate Director, Global Brand Management – Strategy and Operations. Anyone wishing to make this strategic career change will need to have a minimum of 7 years of experience in the pharmaceutical / biotechnology industry.
Senior Partner – Regulatory Affairs. The successful candidate will possess superior decision-making and problem-solving skills and will tend to thrive in a cross-functional business environment. A degree in health or life sciences is required; preferred doctorate.
Category manager, single-use technology. This role is for people passionate about supply chain operations, with over 5 years of strategic sourcing experience and 3+ years in the biotechnology / life sciences industry. BioMarin would prefer someone with an MBA or MS and CPM
Arcus Biosciences, Inc.
Founded in 2015, Arcus Biosciences combines precision therapeutic strategies with the aim of defeating cancers hitherto eluded by medicine. Arcus has clearly been very busy over the past six years, with 13 programs in clinical development and five more in development. Targets include a wide range of cancers, including non-small cell lung cancer (NSCLC), metastatic castration-resistant prostate cancer, and colorectal cancer.
Those looking for a position at this unique biopharmaceutical company should check out some of the more than 90 jobs currently available. Here are a few :
Bioanalytical scientist. Arcus is actively recruiting a scientist for its Metabolism and Pharmacokinetics of Drugs (DMPK) department. Candidates interested with a doctorate in pharmaceutical sciences or related disciplines should apply.
Principal Investigator / Clinical Biomarkers – Translational Science. Arcus is seeking a candidate with expertise in the development, execution and supervision of biomarker plans for active oncology.
Associate Director, Clinical Supply. The successful candidate will play a role in all of Arcus’ clinical development issues. The successful candidate will have more than 7 years of relevant experience and a master’s degree.
Global Blood Therapeutics
Global Blood Therapeutics (GBT) is composed of nearly 400 people driven by the mission of providing life-changing treatments for people with sickle cell disease (SCD) and other serious blood disorders. At the end of 2019, the FDA approved GBT’s oxbryta® (voxelotor) is the first treatment to directly inhibit the polymerization of sickle hemoglobin, the root cause of sickle cell disease. Other investigational drugs include potential treatment to limit the frequency of vaso-occlusive crises (VOCs) and multiple other penalty shootouts for SCD.
Located on Oyster Point Boulevard in South San Francisco, GBT is looking for new talent to fill more than 80 positions, including:
Director, Clinical Operations. GBT is open to hiring the right person to work remotely from anywhere in the United States for this top management position.
Associate Director, Pharmacovigilance Operations. Another remote opportunity for a vigilant leader with 10 or more years of pharmacovigilance experience in an operational and compliance role.
San Francisco-based Nektar Therapeutics focuses on curing cancer and autoimmune diseases using polymer chemistry, a unique approach to drug design that uses optimized pharmacology to create new molecular entities .
Nektar leverages this technology to develop five clinical-stage investigational drugs with partners Bristol Myers Squibb, Biogen, Eli Lilly & Co., and Vaccibodies. The Company’s lead immuno-oncology candidate, bempegaldesleukin, is an IL-2 pathway agonist designed to stimulate the immune system to fight cancer. It is currently being tested in phase III for a number of indications in combination with OPDIVO® from BMS. In February, Nektar ink a co-development agreement with SFJ Pharmaceuticals to advance bempegaldesleukin in head and neck cancer.
With all these programs, it’s no wonder that Nektar is looking for new talent for more than 50 positions. Here are just a couple.
Responsible for clinical trials. If any (or all) of the above programs interest you, this role might be the right fit. The successful candidate will have eight years of pharmaceutical development experience, with at least two years of trial supervision.
Principal Liaison in Medical Sciences (MSL) – North-East. A remote opportunity for a creative, technical and scientific person from the North East.
Sangamo Therapeutics, Inc.
This genomic medicine company touches on many of the hottest areas of biotechnology including gene therapy, cell therapy and in vivo genome editing. Sangamo’s diverse preclinical and clinical pipeline aims to solve life-threatening diseases such as hemophilia A, amyotrophic lateral sclerosis (ALS), phenylketonuria (PKU) and Fabry disease.
In July 2020, Sangamo entered into a collaboration with Novartis to develop and commercialize gene regulatory therapies for three neurodevelopmental targets, including autism spectrum disorders. The agreement is based on Sangamo’s proprietary genome regulation technology, zinc finger protein transcription factors (ZFP-TF), which aims to upregulate gene expression in these disorders.
Anyone wishing to participate in this mission should consult one of the available positions at Sangamo. A Research associate III / IV is one of many associate level opportunities currently on the board. There are also openings for a few science-level positions, including one Research Scientist, Molecular Biology.
This hybrid of cell and gene therapy develops its cell engineering platform to deliver any payload to any cell in a specific, predictable and reproducible way. Sana is targeting this technology towards a wide range of oncological, genetic, CNS and cardiovascular targets in a currently fully preclinical pipeline.
Sana was vocal on its culture of inclusion, diversity and equity (IDE), which management considers essential to its patient-centered culture. By bringing in Farah Anwar, Head of Development Operations, as the head of FDI, Sana ensured that a senior manager was aware of people dynamics as well as medical dynamics.
Sana is currently seeking to integrate a Head of facilities spearhead of its investment project master plan, a Principal Scientist, Core of Genomics advance this key technology, and a Cloud systems administrator to oversee the design.